We recently compiled a list of the 10 Firms Defy Market Pessimism. In this article, we are going to take a look at where Novo ...

As investors look ahead to data shortly from Veru Inc. with enobosarm, the weight-loss space remains hot, with Novo Nordisk A/S reporting favorable top-line results from a phase Ib/IIa trial ...

Here are some of the major companies whose stocks moved on the week’s news.

The Danish pharma giant posted impressive data for amycretin one month after the disappointing readout of CagriSema.

The S&P 500 closed lower after hitting new records on Friday, as investors took some profit to end a solid week centered on President Donald Trump 's return to the White House.

Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 ...

Novo Nordisk shares were 9.5% higher after the pharmaceutical giant said an experimental weight-loss shot showed patients ...

Novo Nordisk stock is paring its year-over-year deficit on positive early stage trial results for the company's new weight ...

On Friday, however, Novo Nordisk announced top-line results in yet another trial. While the results don't initially sound as ...

Novo Nordisk (NVO) stock jumped 12% in pre-market trading Friday after it released promising results of an early-stage weight ...

A novel GLP-1 and amylin receptor agonist featured a safety profile similar to other incretin-based therapies and conferred a ...

In the trial, patients who received a once-weekly 20 mg injection of amycretin over 36 weeks saw an impressive 22% reduction ...